2-苯氧基烟酰胺 | 111950-69-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-苯氧基烟酰胺
• 英文名称: 2-phenoxy-pyridine-3-carboxamide
• 英文别名: phenyloxy-nicotinamide；2-phenoxynicotinamide；phenoxy-nicotinamide；2-phenoxypyridine-3-carboxamide
• CAS: 111950-69-7
• 化学式: C₁₂H₁₀N₂O₂
• mdl: MFCD00052252
• 分子量: 214.224
• InChiKey: FTBCRRFSFTVINJ-UHFFFAOYSA-N

物化性质

• 熔点：
  162-163
• 沸点：
  392.7±27.0 °C(Predicted)
• 密度：
  1.245±0.06 g/cm3(Predicted)
• 溶解度：
  28.8 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  65.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  2-苯氧基烟酰胺 在 potassium tert-butylate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 2-oxo-1,2-dihydropyridine-3-carboxylic acid phenylamide
  参考文献：
  名称：

  基于可调节微笑重排的 N-芳基-烟酰胺和二芳基胺的一锅法合成

  摘要：

  一锅 Smiles 重排已被开发为一种有用的协议，用于直接合成不同的 N-芳基-烟酰胺。该方法还提供了基于酰胺基团的不同取代对二芳基胺的化学选择性途径。转化的潜在应用以市售琥珀酸脱氢酶抑制剂啶酰菌胺的合成为例。

  DOI：

  10.1002/ejoc.201500222

文献信息

• [EN] AMINOBENZOTRIAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS D'AMINOBENZOTRIAZOLE
  申请人：MERCK SHARP & DOHME

  公开号：WO2010114726A1

  公开（公告）日：2010-10-07

  The present invention is directed to aminobenzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

  本发明涉及氨基苯并三唑衍生物，它们是代谢型谷氨酸受体的增效剂，特别是mGluR2受体，对治疗或预防与谷氨酸功能障碍相关的神经和精神疾病以及代谢型谷氨酸受体参与的疾病具有用处。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗代谢型谷氨酸受体参与的这类疾病中使用这些化合物和组合物。
• [EN] NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS<br/>[FR] DERIVES DE NICOTINAMIDE AGISSANT COMME INHIBITEURS DE PDE4
  申请人：PFIZER LTD

  公开号：WO2005009966A1

  公开（公告）日：2005-02-03

  This invention relates to nicotinamide derivatives of formula (I) and to pharmaceutical compositions containing, and the uses of such derivatives as PDE4 inhibitors wherein R7 is attached to the 3- or 4-position of the phenyl ring and is S(O)pR8, R8 is (C1-C4)alkyl optionally substituted by (C3-C6)cycloalkyl; m is 0 or 1; L is a (C3-C8)carbocyclic non-aromatic ring; and the remaining variables are as defined in the claims.

  这项发明涉及式(I)的烟酰胺衍生物，以及含有该类衍生物的药物组合物，以及将这些衍生物用作PDE4抑制剂的用途，其中R7连接到苯环的3-或4-位，并且为S(O)pR8，R8为(C1-C4)烷基，可选择地被(C3-C6)环烷基取代；m为0或1；L为(C3-C8)非芳香环；其余变量如索权中所定义。
• Pyrazole compounds and their use as antidiabetes agents
  申请人：Takagi Masaki

  公开号：US20070032529A1

  公开（公告）日：2007-02-08

  The present invention provides a pyrazole compound that has liver glycogen phosphorylase inhibitory activity and is useful as a therapeutic or prophylactic agent for diabetes, the pyrazole compound represented by the following general formula (I): wherein Ring Q represents an aryl or heteroaromatic group, R 1 represents a hydrogen atom, a halogen atom, a C 1-6 alkyl group or a C 1-6 alkoxy group, R 2 represents a halogen atom, a C 1-6 alkyl group, a C 1-6 alkoxy group or an azido group, R 3 represents a halogen atom, a hydroxyl group, a C 1-6 alkyl group, a halo C 1-6 alkyl group, a C 1-6 alkoxy group, an azido group, an amino group, an acylamino group or a C 1-6 alkylsulfonylamino group, R 4 and R 5 are identical with or different from each other and represent a hydrogen atom, a substituted or unsubstituted C 1-6 alkyl group, a C 3-8 cycloalkyl group, a substituted or unsubstituted saturated heterocyclic group, a substituted or unsubstituted aryl group, a C 7-14 aralkyl group, a heteroaromatic group, or the like, or a pharmacologically acceptable salt thereof.

  本发明提供了一种具有肝糖原磷酸化酶抑制活性的吡唑化合物，用作糖尿病的治疗或预防剂，所述吡唑化合物由以下通用式（I）表示：其中环Q代表芳基或杂芳基，R1代表氢原子、卤原子、C1-6烷基或C1-6烷氧基，R2代表卤原子、C1-6烷基、C1-6烷氧基或偶氮基，R3代表卤原子、羟基、C1-6烷基、卤代C1-6烷基、C1-6烷氧基、偶氮基、氨基、酰胺基或C1-6烷基磺酰胺基，R4和R5彼此相同或不同，代表氢原子、取代或未取代的C1-6烷基、取代或未取代的C3-8环烷基、取代或未取代的饱和杂环基、取代或未取代的芳基、C7-14芳基烷基、杂芳基等，或其药理学上可接受的盐。
• [EN] SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS DE SPHINGOSINE-1-PHOSPHATE
  申请人：EXELIXIS INC

  公开号：WO2010045580A1

  公开（公告）日：2010-04-22

  This disclosure relates to sphingosine-1 -phosphate (SlP) receptor antagonists, compositions comprising the SlP receptor antagonists and methods for using and processes for making the SlP receptor antagonists. In particularly, this disclosure relates to sphingosine-1 -phosphate 1 (SlPl) receptor antagonists, compositions comprising the SlPl receptor antagonist and methods for using the SlPl receptor antagonist, such as in the treatment of cancer, and processes for making the SlPl receptor antagonists.

  这项披露涉及神经酰胺-1-磷酸(S1P)受体拮抗剂，包括该S1P受体拮抗剂的组合物以及使用和制备该S1P受体拮抗剂的方法。特别是，这项披露涉及神经酰胺-1-磷酸1(S1P1)受体拮抗剂，包括该S1P1受体拮抗剂的组合物以及使用该S1P1受体拮抗剂的方法，例如在癌症治疗中，并且包括制备该S1P1受体拮抗剂的方法。
• [EN] MACROLIDE ANTIBIOTICS<br/>[FR] ANTIBIOTIQUES A BASE DE MACROLIDES
  申请人：GLAXO GROUP LTD

  公开号：WO2002050091A1

  公开（公告）日：2002-06-27

  The present invention relates to 11,12 η lactone ketolides of formula (I) wherein R, R?1, R2, R3¿ are as defined herein and pharmaceutically acceptable salts and solvates thereof, to process for their preparation and their use in therapy or prophylaxis of systemic or topical bacterial infections in a human or animal body.

  本发明涉及式（I）的11,12-η内酯酮类化合物，其中R，R?1，R2，R3¿如本文所定义，并且其药学上可接受的盐和溶剂合物，以及其制备过程和在治疗或预防人类或动物体内的全身性或局部细菌感染中的应用。